Search Results - "Savla, Ronak"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Review and analysis of FDA approved drugs using lipid-based formulations by Savla, Ronak, Browne, Jeff, Plassat, Vincent, Wasan, Kishor M., Wasan, Ellen K.

    Published in Drug development and industrial pharmacy (02-11-2017)
    “…Lipid-based drug delivery systems (LBDDS) are one of the most studied bioavailability enhancement technologies and are utilized in a number of U.S. Food and…”
    Get full text
    Journal Article
  2. 2

    Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells by Xiao, Yan, Gao, Xiugong, Taratula, Oleh, Treado, Stephen, Urbas, Aaron, Holbrook, R David, Cavicchi, Richard E, Avedisian, C Thomas, Mitra, Somenath, Savla, Ronak, Wagner, Paul D, Srivastava, Sudhir, He, Huixin

    Published in BMC cancer (02-10-2009)
    “…Nanocarrier-based antibody targeting is a promising modality in therapeutic and diagnostic oncology. Single-walled carbon nanotubes (SWNTs) exhibit two unique…”
    Get full text
    Journal Article
  3. 3

    Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes by Taratula, Oleh, Garbuzenko, Olga, Savla, Ronak, Wang, Y Andrew, He, Huixin, Minko, Tamara

    Published in Current drug delivery (01-01-2011)
    “…The ability of Superparamagnetic Iron Oxide (SPIO) nanoparticles and Poly(Propyleneimine) generation 5 dendrimers (PPI G5) to cooperatively provoke siRNA…”
    Get more information
    Journal Article
  4. 4

    Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids by Shah, Vatsal, Taratula, Oleh, Garbuzenko, Olga B, Patil, Mahesh L, Savla, Ronak, Zhang, Min, Minko, Tamara

    Published in Current drug discovery technologies (01-03-2013)
    “…The prevention of cyto- and genotoxicity of nanocarriers is an important task in nanomedicine. In the present investigation, we, at the first time using…”
    Get more information
    Journal Article
  5. 5

    Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value by Savla, Ronak, Minko, Tamara

    Published in Advanced drug delivery reviews (01-04-2017)
    “…The present review analyzes various approaches for the design and synthesis of different nanoparticles for imaging and therapy. Nanoparticles for computed…”
    Get full text
    Journal Article
  6. 6

    Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer by Savla, Ronak, Taratula, Oleh, Garbuzenko, Olga, Minko, Tamara

    Published in Journal of controlled release (15-07-2011)
    “…In this study, we report the design and delivery of a tumor-targeted, pH-responsive quantum dot-mucin1 aptamer-doxorubicin (QD-MUC1-DOX) conjugate for the…”
    Get full text
    Journal Article Conference Proceeding
  7. 7

    Nanotechnology approaches for inhalation treatment of fibrosis by Savla, Ronak, Minko, Tamara

    Published in Journal of drug targeting (01-12-2013)
    “…Abstract Cystic fibrosis (CF) is an autosomal recessive monogenetic disease that afflicts nearly 70 000 patients worldwide. The mutation results in the…”
    Get full text
    Journal Article
  8. 8

    Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy by Savla, Ronak, Garbuzenko, Olga B., Chen, Suzie, Rodriguez-Rodriguez, Lorna, Minko, Tamara

    Published in Pharmaceutical research (01-12-2014)
    “…Purpose Design and synthesis of a tumor responsive nanoparticle-based system for imaging and treatment of various cancers. Methods Manganese oxide…”
    Get full text
    Journal Article
  9. 9

    Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery by Taratula, Oleh, Garbuzenko, Olga B., Kirkpatrick, Paul, Pandya, Ipsit, Savla, Ronak, Pozharov, Vitaly P., He ⁎, Huixin, Minko, Tamara

    Published in Journal of controlled release (16-12-2009)
    “…Low penetration ability of Small Interfering RNA (siRNA) through the cellular plasma membrane combined with its limited stability in blood, limits the…”
    Get full text
    Journal Article Conference Proceeding
  10. 10

    Insights and Lessons from a Scientific Conference on Non-Invasive Delivery of Macromolecules by Savla, Ronak, Mrsny, Randall J., Park, Kinam, Aubert, Isabelle, Stamoran, Cornell

    Published in Pharmaceutical research (01-06-2017)
    “…A growing share of the pharmaceutical development pipeline is occupied by macromolecule drugs, which are primarily administered by injection. Despite decades…”
    Get full text
    Journal Article Conference Proceeding
  11. 11

    Abstract 4405: Tumor-targeted nanotherapeutics by Garbuzenko, Olga B., Kuzmov, Andriy, Sapiezynski, Justin E., Taratula, Oleh, Shah, Vatsal, Zhang, Min, Savla, Ronak, John, Shali, Rodriguez-Rodriguez, Lorna, Minko, Tamara

    Published in Cancer research (Chicago, Ill.) (01-08-2015)
    “…Abstract Directing anticancer agents specifically to tumors and/or cancer cells by targeting specific extracellular receptors fulfills the following three most…”
    Get full text
    Journal Article
  12. 12

    Tumor responsive targeted multifunctional nanosystems for cancer imaging, chemo- and siRNA therapy by Savla, Ronak

    Published 01-01-2015
    “…Cancer is one of the most insidious diseases. Compromising of over 100 different types and sharing the unifying factors of uncontrolled growth and metastasis,…”
    Get full text
    Dissertation
  13. 13

    Tumor responsive targeted multifunctional nanosystems for cancer imaging, chemo- and siRNA therapy by Savla, Ronak

    “…Cancer is one of the most insidious diseases. Compromising of over 100 different types and sharing the unifying factors of uncontrolled growth and metastasis,…”
    Get full text
    Dissertation
  14. 14

    Bridging the Gap from Molecule to Drug by Tindal, Stephen, Savla, Ronak

    Published in Pharmaceutical Technology (01-04-2018)
    “…Molecule development and dosage form selection In small companies, these two phases in product development, though part of a continuum, are hampered by an…”
    Get full text
    Trade Publication Article
  15. 15
  16. 16